Technical Analysis for OPK - OPKO Health Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Inside Day | Range Contraction | -3.27% | |
Gapped Up | Strength | -3.27% | |
Oversold Stochastic | Weakness | -3.27% | |
New 52 Week Closing Low | Bearish | -2.25% | |
Below Lower BB | Weakness | -2.25% | |
Down 3 Days in a Row | Weakness | -2.25% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 13 hours ago |
Down 3% | about 13 hours ago |
Fell Below Lower Bollinger Band | about 14 hours ago |
Down 2 % | about 14 hours ago |
Down 1% | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
OPKO Health Inc. Description
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Infectious Diseases Autoimmune Disease Pharmaceutical Products Alzheimer's Disease Phosphates Chemotherapy Prostate Cancer Non Small Cell Lung Cancer Vitamins Clinical Trial Antibiotics Kidney Disease Medical Test Ophthalmic Pancreatic Cancer Small Cell Lung Cancer Dialysis Influenza Biomarkers Asthma Diagnostic Tests Molecular Diagnostics Chronic Obstructive Pulmonary Disease Hormones Pulmonary Disease Thyroid Active Pharmaceutical Ingredients Heart Disease Chronic Kidney Disease End Stage Renal Disease Hemodialysis Renal Disease Metabolic Disorders Oligonucleotide Stage Renal Disease Pathology Influenza Vaccine Medical Laboratory Nausea Organ Failure Vascular Products Cardiovascular Products Heparin Chemotherapy Induced Nausea Hyperparathyroidism Hyperphosphatemia OLAP Opko Health Secondary Hyperparathyroidism
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.24 |
52 Week Low | 0.8516 |
Average Volume | 13,559,570 |
200-Day Moving Average | 1.46 |
50-Day Moving Average | 0.98 |
20-Day Moving Average | 0.96 |
10-Day Moving Average | 0.92 |
Average True Range | 0.05 |
RSI (14) | 32.89 |
ADX | 20.36 |
+DI | 12.59 |
-DI | 27.49 |
Chandelier Exit (Long, 3 ATRs) | 0.92 |
Chandelier Exit (Short, 3 ATRs) | 1.01 |
Upper Bollinger Bands | 1.05 |
Lower Bollinger Band | 0.87 |
Percent B (%b) | 0.0 |
BandWidth | 19.73 |
MACD Line | -0.04 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.006 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.93 | ||||
Resistance 3 (R3) | 0.94 | 0.92 | 0.92 | ||
Resistance 2 (R2) | 0.92 | 0.91 | 0.92 | 0.92 | |
Resistance 1 (R1) | 0.89 | 0.90 | 0.89 | 0.89 | 0.92 |
Pivot Point | 0.88 | 0.88 | 0.87 | 0.87 | 0.88 |
Support 1 (S1) | 0.85 | 0.86 | 0.84 | 0.84 | 0.82 |
Support 2 (S2) | 0.83 | 0.85 | 0.83 | 0.81 | |
Support 3 (S3) | 0.80 | 0.83 | 0.81 | ||
Support 4 (S4) | 0.80 |